References
- Batlevi CL, Younes A. Novel therapy for Hodgkin lymphoma. Hematology. 2013;2013(1):394–9. doi:https://doi.org/10.1182/asheducation-2013.1.394.
- Carey CD, Gusenleitner D, Lipschitz M, Roemer MGM, Stack EC, Gjini E, Hu X, Redd R, Freeman GJ, Neuberg D, et al. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood. 2017;130(22):2420–30. doi:https://doi.org/10.1182/blood-2017-03-770719.
- Kennedy-Nasser AA, Hanley P, Bollard CM. Hodgkin disease and the role of the immune system. Pediatr Hematol Oncol. 2011;28(3):176–86. doi:https://doi.org/10.3109/08880018.2011.557261.
- Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26(1):677–704. doi:https://doi.org/10.1146/annurev.immunol.26.021607.090331.
- Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, Connelly CF, Sun HH, Daadi SE, Freeman GJ, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016;34(23):2690–7. doi:https://doi.org/10.1200/JCO.2016.66.4482.
- Paydas S, Bağır E, Seydaoglu G, Ercolak V, Ergin M. Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma. Ann Hematol. 2015;94(9):1545–52. doi:https://doi.org/10.1007/s00277-015-2403-2.
- de la Cruz-Merino L, Lejeune M, Nogales Fernández E, Henao Carrasco F, Grueso López A, Illescas Vacas A, Pulla MP, Callau C, Álvaro T. Role of immune escape mechanisms in Hodgkin’s lymphoma development and progression: a whole new world with therapeutic implications. Clin Dev Immunol. 2012;2012:1–24. doi:https://doi.org/10.1155/2012/756353.
- Gul G, Ince D, Olgun N, Ozer E. PD-L1 and PD-L2 mutations in paediatric Hodgkin Lymphoma: do they have any prognostic significance? Virchows Arch. 2019;475(1 Suppl):S159. https://doi.org/10.1007/s00428-019-02631-8
- Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. doi:https://doi.org/10.1016/j.immuni.2013.07.012.
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi:https://doi.org/10.1016/j.cell.2011.02.013.
- Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64. doi:https://doi.org/10.1038/nrc3239.
- Guan J, Lim KS, Mekhail T, Chang CC. Programmed death ligand-1 (PD-L1) expression in the programmed death receptor-1 (PD-1)/PD-L1 blockade: a key player against various cancers. Arch Pathol Lab Med. 2017;141(6):851–61. doi:https://doi.org/10.5858/arpa.2016-0361-RA.
- Robainas M, Otano R, Bueno S, Ait-Oudhia S. Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy. OncoTargets Ther. 2017;10:1803–7. doi:https://doi.org/10.2147/OTT.S132508.
- Shi L, Chen S, Yang L, Li Y. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol. 2013;6(1):74. doi:https://doi.org/10.1186/1756-8722-6-74.
- Vranic S, Ghosh N, Kimbrough J, Bilalovic N, Bender R, Arguello D, Veloso Y, Dizdarevic A, Gatalica Z. PD-L1 Status in refractory lymphomas. PLoS One. 2016;11(11):e0166266. doi:https://doi.org/10.1371/journal.pone.0166266.
- Georgiou K, Chen L, Berglund M, Ren W, de Miranda NFCC, Lisboa S, Fangazio M, Zhu S, Hou Y, Wu K, et al. Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. Blood. 2016;127(24):3026–34. doi:https://doi.org/10.1182/blood-2015-12-686550.
- Atanackovic D, Luetkens T, Kröger N. Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia. 2014;28(5):993–1000. doi:https://doi.org/10.1038/leu.2013.310.
- Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MGM, Xu ML, Yu H, Fletcher CDM, Freeman GJ, Shipp MA, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19(13):3462–73. doi:https://doi.org/10.1158/1078-0432.
- Ribas A, Hu-Lieskovan S. What does PD-L1 positive or negative mean? J Exp Med. 2016;213(13):2835–40. doi:https://doi.org/10.1084/jem.20161462.
- Reichel J, Chadburn A, Rubinstein PG, Giulino-Roth L, Tam W, Liu Y, Gaiolla R, Eng K, Brody J, Inghirami G, et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood. 2015;125(7):1061–72. doi:https://doi.org/10.1182/blood-2014-11-610436.
- Gato-Cañas M, Zuazo M, Arasanz H, Ibañez-Vea M, Lorenzo L, Fernandez-Hinojal G, Vera R, Smerdou C, Martisova E, Arozarena I, et al. PDL1 Signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity. Cell Rep. 2017;20(8):1818–29. doi:https://doi.org/10.1016/j.celrep.2017.07.075.
- Hamer I, Foti M, Emkey R, Cordier-Bussat M, Philippe J, De Meyts P, Maeder C, Kahn CR, Carpentier JL. An arginine to cysteine (252) mutation in insulin receptors from a patient with severe insulin resistance inhibits receptor internalization but preserves signaling events. Diabetologia. 2002;45(5):657–67. doi:https://doi.org/10.1007/s00125-002-0798-5.